Baqsimi
- Product NDC
- 0002-6145
- 11-digit product format
- 000026145
- Labeler code
- 0002
- Product ID
- 0002-6145_f88837b4-7c0d-4200-aba0-e92561310058
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- glucagon
- Dosage form
- POWDER
- Route
- NASAL
- Labeler
- Eli Lilly and Company
- Application
- NDA210134
- Marketing category
- NDA
- Marketing start
- 2019-07-24
- Marketing end
- 0000-00-00
- Substance
- GLUCAGON
- Active strength
- 3 mg/1
- Pharmacologic classes
- Antihypoglycemic Agent [EPC],Gastrointestinal Motility Inhibitor [EPC],Increased Gluconeogenesis [PE],Increased Glycogenolysis [PE],Decreased GI Smooth Muscle Tone [PE],Decreased GI Motility [PE],Decreased Glycolysis [PE]
- NDC exclude flag
- No
- Listing certified through
- 2022-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 0002-6145 | BAQSIMI (GLUCAGON) POWDER [ELI LILLY AND COMPANY] | 7 | Legacy NDC | 20241213_3fdb4e92-2e19-487d-9f14-99871e9fd15a.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 0002-6145-11 | 00002614511 | 1 TUBE in 1 CARTON (0002-6145-11) > 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) > 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01) | 1 tube | 2019-08-06 | 0000-00-00 | No | No | Current |
| 0002-6145-27 | 00002614527 | 2 TUBE in 1 CARTON (0002-6145-27) > 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) > 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01) | 2 tube | 2019-08-06 | 0000-00-00 | No | No | Current |